Physician profile
Stephen D Raphael
NPI 1477599702
$1,860.56
in general payments reported to CMS, 2019-2025
21 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.93 · 2020: $294 · 2021: $544 · 2022: $402 · 2023: $174 · 2024: $150 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $565.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $502.30 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $450.59 | 2019-2025 | Airsupra, Breztri |
| Exact Sciences Corporation | $144.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bausch Health US, LLC | $129.41 | 2020-2021 | |
| Amarin Pharma, INC. | $125.76 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $82.39 | 2022-2023 | Seglentis, Livalo |
| Lilly USA, LLC | $77.95 | 2022-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $62.64 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.92 | 2024-2025 | Xifaxan |
| Novo Nordisk INC | $37.84 | 2025 | |
| Axsome Therapeutics, INC. | $35.88 | 2024-2025 | Auvelity |
| Amgen INC. | $30.93 | 2025 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $18.50 | 2024 | Arexvy, Trelegy Ellipta |
| Hikma Pharmaceuticals USA | $16.12 | 2019 | |
| Corium, LLC | $15.73 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Althera Pharmaceuticals LLC | $15.00 | 2021 | |
| Astellas Pharma US INC | $14.80 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.18 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.60 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.15 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Raphael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.